Cite
MLA Citation
Benjamin Fisher et al.. “FRI0174 SUBCUTANEOUS DOSING OF THE NOVEL ANTI-CD40 ANTIBODY ISCALIMAB ACHIEVES TARGET DRUG EXPOSURE AND CLINICAL EFFICACY IN PRIMARY SJÖGREN'S SYNDROME; RESULTS OF A PHASE IIA RANDOMISED OPEN LABEL TWO ARM PARALLEL GROUP TRIAL.” Annals of the rheumatic diseases, vol. 78, n.d., pp. 760–761. http://access.bl.uk/ark:/81055/vdc_100144728922.0x000057